Netherlands-based Mylan (Nasdaq: MYL) has reached an agreement with the US Department of Justice, finalizing the previously announced Medicaid drug rebate settlement of $465 million.
The firm’s shares took a beating last year amid controversy, including a congressional hearing, over the classification of EpiPen (epinephrine) products as non-innovator drugs, which led to lower rebate payments to Medicaid.
Since first revealing the settlement, Mylan has posted upbeat financial guidance for the year. The near-half billion dollar payment was booked in the company’s 2016 accounts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze